{"nctId":"NCT01545076","briefTitle":"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)","startDateStruct":{"date":"2012-03"},"conditions":["Chronic Inflammatory Demyelinating Polyneuropathy","Polyradiculoneuropathy"],"count":208,"armGroups":[{"label":"IgPro20 low dose","type":"EXPERIMENTAL","interventionNames":["Biological: IgPro20 (low dose)","Biological: IgPro10"]},{"label":"IgPro20 high dose","type":"EXPERIMENTAL","interventionNames":["Biological: IgPro10","Biological: IgPro20 (high dose)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Biological: Placebo","Biological: IgPro10"]}],"interventions":[{"name":"IgPro20 (low dose)","otherNames":["Hizentra"]},{"name":"Placebo","otherNames":[]},{"name":"IgPro10","otherNames":[]},{"name":"IgPro20 (high dose)","otherNames":["Hizentra"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Definite or probable CIDP according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) criteria 2010.\n* An IVIG treatment during the last 8 weeks prior to enrollment.\n* Age â‰¥18 years.\n* Written informed consent for study participation obtained before undergoing any study-specific procedures.\n\nExclusion Criteria:\n\n* Any polyneuropathy of other causes\n* Any other disease (mainly neurological or chronic orthopedic) that has caused neurological symptoms or may interfere with treatment or outcome assessments\n* Severe diseases and conditions that are likely to interfere with evaluation of the study product or satisfactory conduct of the study\n* History of thrombotic episodes within the 2 years prior to enrolment\n* Known allergic or other severe reactions to blood products including intolerability to previous IVIG","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage (%) of Subjects With CIDP Relapse or Are Withdrawn for Any Other Reason During the Subcutaneous (SC) Treatment Period","description":"Relapse is defined as an increase of at least 1 INCAT score point (except for the increase from 0 to 1 in the upper limb score). The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 (\"No upper limb problems\") to 5 (\"Inability to use either arm for any purposeful movement\"), and scores for leg disability range from 0 (\"Walking not affected\") to 5 (\"Restricted to wheelchair, unable to stand and walk a few steps with help\"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the \"adjusted\" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.8","spread":null},{"groupId":"OG001","value":"38.6","spread":null},{"groupId":"OG002","value":"63.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Inflammatory Neuropathy Cause and Treatment (INCAT) Scores During the SC Treatment Period","description":"The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 (\"No upper limb problems\") to 5 (\"Inability to use either arm for any purposeful movement\"), and scores for leg disability range from 0 (\"Walking not affected\") to 5 (\"Restricted to wheelchair, unable to stand and walk a few steps with help\"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the \"adjusted\" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Change From Baseline in the Mean Grip Strength Scores of the Dominant Hand During the SC Treatment Period","description":"The hand-held Vigorimeter is a device that measures the strength of small muscles in the hand; ie, grip strength. Subjects squeezed a rubber bulb lying between the palm of the hand and the thumb and index fingers. The pressure was recorded via a rubber tube on a nanometer and expressed in kilopascal. At each assessment, the subjects squeezed 3 times with each hand. The mean grip strength median score of the dominant hand was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":null},{"groupId":"OG001","value":"-0.6","spread":null},{"groupId":"OG002","value":"-6.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in the Medical Research Council (MRC) Sum Scores During the SC Treatment Period","description":"An adapted version of the MRC sum score was used in the study. The MRC sum score is the sum of all 16 muscle scores, and ranges from 0 (paralysis) to 80 (normal strength).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"-2","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Rasch-built Overall Disability Scale (R-ODS) Scores During the SC Treatment Period","description":"The R-ODS centile score captures activity and social participation in subjects with CIDP. The R-ODS centile score ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"-2","spread":null},{"groupId":"OG002","value":"-3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to CIDP Relapse or Withdrawal Due to Any Other Reason During the SC Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"NA","spread":null},{"groupId":"OG002","value":"79.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events Per IgPro20 Infusion During the SC Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.051","spread":null},{"groupId":"OG001","value":"0.079","spread":null},{"groupId":"OG002","value":"0.034","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events During the SC Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"21","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With Adverse Events During the SC Treatment Period","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"57.9","spread":null},{"groupId":"OG002","value":"36.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Improvement During IgPro10 Re-stabilization Therapy","description":"Improvement is defined as an INCAT score decrease by 1 point (except for the decrease from 1 to 0 in the upper limb score), R-ODS improvement by at least 4 points, Mean Grip strength improvement by at least 8 kPa in one hand, or MRC Sum score \\>=3.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Grip Strength During IgPro10 Re-stabilization Therapy","description":"The hand-held Vigorimeter is a device that measures the strength of small muscles in the hand; ie, grip strength. Subjects squeezed a rubber bulb lying between the palm of the hand and the thumb and index fingers. The pressure was recorded via a rubber tube on a nanometer and expressed in kilopascal. At each assessment, the subjects squeezed 3 times with each hand. The mean grip strength median score of the dominant hand was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.27","spread":"16.89"}]}]}]},{"type":"SECONDARY","title":"Change in MRC Sum Score During IgPro10 Re-stabilization Therapy","description":"An adapted version of the MRC sum score was used in the study. The MRC sum score is the sum of all 16 muscle scores, and ranges from 0 (paralysis) to 80 (normal strength).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"4.9"}]}]}]},{"type":"SECONDARY","title":"Change in R-ODS During IgPro10 Re-stabilization Therapy","description":"The R-ODS centile score captures activity and social participation in subjects with CIDP. The R-ODS centile score ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.7","spread":"14.14"}]}]}]},{"type":"SECONDARY","title":"Change in INCAT During IgPro10 Re-stabilization Therapy","description":"The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 (\"No upper limb problems\") to 5 (\"Inability to use either arm for any purposeful movement\"), and scores for leg disability range from 0 (\"Walking not affected\") to 5 (\"Restricted to wheelchair, unable to stand and walk a few steps with help\"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the \"adjusted\" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"1.2"}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events Per IgPro10 Infusion During Re-stabilization Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.175","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events During IgPro10 Re-stabilization Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Adverse Events During IgPro10 Re-stabilization Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Improvement After CIDP Relapse During IgPro10 Rescue Therapy","description":"Improvement is defined as a decrease in INCAT score (except for the decrease from 1 to 0 in the upper limb score) back to or below the baseline score..The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 (\"No upper limb problems\") to 5 (\"Inability to use either arm for any purposeful movement\"), and scores for leg disability range from 0 (\"Walking not affected\") to 5 (\"Restricted to wheelchair, unable to stand and walk a few steps with help\"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the \"adjusted\" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Adverse Events Per IgPro10 Infusion During Rescue Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.142","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Adverse Events During IgPro10 Rescue Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent of Subjects With Adverse Events During IgPro10 Rescue Therapy","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Mean Grip Strength During IgPro10 Rescue Therapy","description":"The hand-held Vigorimeter is a device that measures the strength of small muscles in the hand; ie, grip strength. Subjects squeezed a rubber bulb lying between the palm of the hand and the thumb and index fingers. The pressure was recorded via a rubber tube on a nanometer and expressed in kilopascal. At each assessment, the subjects squeezed 3 times with each hand. The mean grip strength median score of the dominant hand was determined.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3","spread":"17.58"}]}]}]},{"type":"SECONDARY","title":"Change in MRC Sum Score During IgPro10 Rescue Therapy","description":"An adapted version of the MRC sum score was used in the study. The MRC sum score is the sum of all 16 muscle scores, and ranges from 0 (paralysis) to 80 (normal strength).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":"5.28"}]}]}]},{"type":"SECONDARY","title":"Change in R-ODS During IgPro10 Rescue Therapy","description":"The R-ODS centile score captures activity and social participation in subjects with CIDP. The R-ODS centile score ranges from 0 (most severe activity and social participation limitations) to 100 (no activity and social participation limitations).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"14.69"}]}]}]},{"type":"SECONDARY","title":"Change in INCAT During IgPro10 Rescue Therapy","description":"The INCAT score is a 10-point scale that covers the functionality of legs and arms, and has been successfully used to measure treatment effects in various CIDP studies. Scores for arm disability range from 0 (\"No upper limb problems\") to 5 (\"Inability to use either arm for any purposeful movement\"), and scores for leg disability range from 0 (\"Walking not affected\") to 5 (\"Restricted to wheelchair, unable to stand and walk a few steps with help\"). The INCAT (total) score is the sum of these 2 scores and ranges from 0 to 10. For the \"adjusted\" INCAT score, changes in the function of the upper limbs from 0 (normal) to 1 (minor symptoms) or from 1 to 0 were not recorded as deterioration or improvement because these changes are not considered clinically significant.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.31"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":207},"commonTop":["Headache","Nasopharyngitis","Nausea","Infusion site erythema","Infusion site swelling"]}}}